Stocks · News reference
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of $(0.13) per share from
Read original at benzingaFiled: 2026-08-13 AccNo: 0001193125-26-349170 Size: 430 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarWall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
Read original at benzingaTop Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.
Read original at benzinga